The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•27 March 2026•

1 min read

Deutsche Bank Initiates Coverage on AtaiBeckley with Buy Rating and $12 Target

Key Facts

1Deutsche Bank analysts initiated coverage on AtaiBeckley with a 'Buy' rating and a $12 price target.

2The price target implies a potential upside of approximately 320% from current levels.

Deutsche Bank analysts have officially initiated coverage on AtaiBeckley (ATAI) with a 'Buy' rating, signaling a bullish outlook for the biotech firm's future. The bank set a price target of $12 per share, suggesting a massive potential upside of approximately 320% from current market levels. In their report, analysts highlighted the company's strategic positioning within the emerging field of psychedelic medicine for mental health treatments. Deutsche Bank views AtaiBeckley as a leader in this developing sector, which aims to address complex mental health conditions through innovative therapies. The initiation of coverage by a major global financial institution is expected to serve as a significant catalyst for investor interest in the stock. Market participants are closely watching the company's clinical progress as it gains momentum following this high-conviction endorsement.